Background and Purpose: The Na + /Ca 2+ exchanger (NCX) working in either forward or reverse mode participates in maintaining intracellular Ca 2+ ([Ca 2+ ] i ) homeostasis, which is essential for determining cell fate. Previously, numerous blockers targeting reverse or forward NCX have been developed and studied in ischaemic tissue injury but barely examined in glioblastoma for the purpose of anti-tumour therapy. We assessed the effect of NCX blockers on glioblastoma growth and whether NCX can become a therapeutic target.
| INTRODUCTION
Intracellular Ca 2+ signalling plays an important role in cell fate determination such as quiescence or proliferation, survival, or death and, therefore, is receiving increasing attention in the study of glioblastoma evolution (Leclerc et al., 2016; Morrone, Gehring, & Nicoletti, 2016) .
Tumour biology studies document that glioblastoma cells release toxic concentrations of glutamate to surrounding neurons (Buckingham et al., 2011; Ye & Sontheimer, 1999) . Glutamate constantly activates glutamate receptors in glioblastoma cells and causes Ca 2+ influx. If Ca 2+ extrusion mechanisms are inhibited, the intracellular Ca 2+ ([Ca 2+ ] i ) will build up in glioblastoma cells. The accumulation of [Ca 2+ ] i is a well-known step that causes ischaemic/hypoxic cell death (Dong, Saikumar, Weinberg, & Venkatachalam, 2006; Trump & Berezesky, 1995) . An elevation of [Ca 2+ ] i may also be lethal to tumour cells and become a new approach for combating glioblastoma.
However, the data regarding how to induce [Ca 2+ ] i overload and Ca 2+ -dependent injury in glioblastoma are very limited (Hsu et al., 2016; Liang & Lu, 2012) .
The Na + /Ca 2+ exchanger (NCX) is an anti-porter located in the plasma membrane. NCX participates in maintaining intracellular Ca 2+ homeostasis by working either in the forward mode (Ca 2+ extrusion) or in the reverse mode (Ca 2+ entry) depending on the membrane potential and the transmembrane Ca 2+ and Na + concentrations Nagy et al., 2004) . The mammalian NCX (SLC8) family contains three isoforms, NCX1, NCX2, and NCX3. NCX1 predominately exists in neurons, glial cells, cardiomyocytes, and renal tissue, while NCX2-NCX3 barely appear in tissues other than brain and skeletal muscle (Annunziato, Pignataro, & Di Renzo, 2004) . NCX and the plasma membrane Ca 2+ -ATPase are the main Ca 2+ transporters that are in charge of extruding [Ca 2+ ] i in neurons and glial cells (Blaustein, Juhaszova, Golovina, Church, & Stanley, 2002) . The NCX has 20-fold to 60-fold higher Ca 2+ -transporting capacity than plasma membrane Ca 2+ -ATPase (Herchuelz, Kamagate, Ximenes, & Van Eylen, 2007) , so NCX is the primary means of Ca 2+ extrusion when [Ca 2+ ] i accumulates above the basal level. Inhibition of the NCX occludes the main route of Ca 2+ extrusion and thus will result in [Ca 2+ ] i overload. To validate this speculation, we examined whether NCX blockers can elevate [Ca 2+ ] i in glioblastoma cells and induce Ca 2+ -dependent cell death.
Over the past 20 years, many NCX blockers have been developed and employed to study the pathological role of NCX in hypoxic/ ischaemic brain, heart, and renal tissue (Pignataro, Gala, et al., 2004; Shenoda, 2015) . Bepridil is often used as a forward NCX blocker in pharmacological studies; however, it also partially inhibits the reverse NCX and affects some K + and Ca 2+ channels in animal cardiomyocytes Ma, Takanari, Masuda, Morishima, & Ono, 2016; Wang, Kiyosue, Kiriyama, & Arita, 1999; Watanabe & Kimura, 2001) . CB-DMB is a more specific blocker for inhibiting the forward mode of NCX (Amoroso et al., 1997; Annunziato et al., 2004) .
KB-R7943 is a blocker that inhibits the NCX in both operation modes (Watano, Harada, Harada, & Nishimura, 1999) . Inhibition of forward NCX by bepridil aggravates ischaemic brain damage, whereas inhibitors that selectively target the reverse NCX, such as SEA0400, SN-6, and YM-244769, produce protection in various hypoxic/ ischaemic cell injury models (Hu & Song, 2017; . Thus, pharmacological effects of NCX blockers rely on what mode of NCX operation is blocked at a given time. Theoretically, inhibition of the reverse NCX impedes NCX-mediated Ca 2+ entry and reduces Ca 2+ -mediated injury. In contrast, blockade of the forward NCX (Ca 2+ efflux) will lead to Ca 2+ accumulation and cytotoxicity.
Given that NCX blockers have been well developed and studied, it is timely and of great interest to know what action these NCX blockers will exert on glioblastoma. Particularly, involvement of the NCX in glioblastoma growth has not been well studied using either pharmacological or genetic approaches (Amoroso et al., 1997; Hsu, Chou, & Chueh, 1995) .
Here, we showed that blocking reverse NCX with its selective inhibitors does not affect tumour growth; the glioblastoma is only suppressed when the forward NCX is blocked. Blocking the forward NCX is an effective strategy to beat glioblastoma. Therefore, the plasma membrane NCX may represent a new potential therapeutic target.
| METHODS

| Animals and ethical statement
Male athymic BALB/c nude mice were provided by Shanghai Laboratory Animal Center (Chinese Academy of Sciences, Shanghai, China).
BALB/c nude mouse was developed through crosses and backcrosses
What is already known • A host of NCX blockers has been developed and studied in tissues other than glioblastoma.
What this study adds
• Blocking the forward but not reverse NCX can suppress glioblastoma growth via Ca 2+ -mediated injury.
What is the clinical significance
• The NCX is a potential therapeutic target, and bepridil could be a leading compound.
• Summarized in 50 words, the significance of the work in language can be understood by a first-year university science student, including what this paper adds to existing literature.
• Existing literature shows that the Na + /Ca 2+ exchanger (NCX) and its blockers have been studied in tissues other than glioblastoma. We here found that blocking the forward NCX with bepridil can kill glioblastoma. We suggest that the NCX is a potential therapeutic target and bepridil could be a lead compound for this strategy.
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between BALB/cABom-nu and BALB/cAnNCrj-nu at Charles River Laboratories Japan, Inc.; this mouse is inbred, and genetic monitoring results confirm it to be a BALB/c nude. The animal lacks a thymus, is unable to produce T cells, and is therefore immunodeficient. Mice were housed in the specific pathogen-free animal facility with free access to food and water and a 12-hr light to dark cycle. 
| Nucleoprotein extraction
Adherent cells were washed twice with 10 ml Dulbecco's PBS. Then 1-mM PMSF, 1-mM DTT, and 10-μl protease inhibitor cocktail (without EDTA) per 1 ml of hypotonic buffer, mix hypotonic buffer, were added and samples placed on ice for a few minutes. After which 0.6-ml mixed hypotonic buffer was added per 10,000,000 cells, on ice, then cells scraped off, and samples transferred to 1.5-ml EP tube, centrifuged for 5 min (4°C, 835× g), and the supernatant removed. The cell lysates were resuspended by adding 0.6-ml hypotonic buffer, centrifuged for 5 min (4°C, 835× g), and the supernatant removed. The pellet was resuspended in 0.3 ml of lysis buffer (lysis buffer contained 1-mM PMSF, 1-mM DTT, and 10-μl protease inhibitor cocktail per 1 ml of lysis buffer), incubated on ice for 20 min, and centrifuged for 10 min (4°C, 13,362× g). The supernatant was nuclear protein extraction.
| U87-luciferase xenograft model and treatment
The athymic BALB/c nude mice were anaesthetized by subjecting them to 3% isoflurane (RWD Life Science, Shenzhen, China) in a mixture of 30% O 2 and 70% N 2 O. After induction of anaesthesia, 1.5% isoflurane was maintained, and body temperature was kept at 37 ± 0.5°C by a heating pad. The mouse head was maintained within a stereotactic frame (RWD Life Science), allowing a precise and reproducible injection. The coordinate of the injection site was 0.5 mm anterior and 2.5 mm right from the bregma and at a depth of 3 mm.
U87-Luc cells (COBIOER) were assessed by the trypan blue exclusion assay. Only cell suspensions with greater than 95% viability were used and implanted into the right striatum of nude mice. U87-Luc cells (5 × 10 5 in 5-μl PBS) were inoculated into the right striatum of each mouse at a controlled flow rate of 0.5 μl·min −1 , and the total injection volume was about 5 μl. Sixteen days after implantation, the mice were randomly divided into two groups: treated with vehicle (n = 5) and treated with bepridil (n = 5). Bepridil was first dissolved in ethanol (final volume 5%) and then added to a mixture of polyethylene glycol (50%) and 0.9% NaCl (45%). Mice received bepridil (50 mg·kg −1 body weight) or vehicle treatment once a day via oral gavage for 14 days.
Drug treatment was performed by a person who was blinded to the experimental groups.
| MS analysis
Athymic BALB/c nude mice were administered bepridil by oral gavage at doses of 50 mg·kg −1 as described above. Two hours later, mice were killed, and the brain sample was homogenized using the tissue homogenizers (Bertin Instruments, Paris, France) in ice-cold deionized water at a concentration of 3 ml·g −1 tissue. Then, methanol with 0.1% formic acid was added to the brain homogenate in a 4:1 proportion (vol/vol) and centrifuged at 18,188× g and 4°C for 10 min to precipitate protein. The supernatant was transferred to a vial to be injected directly into the LC-MS. 
| Materials
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMA-COLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander, Fabbro et al., 2017; . amplitudes measured in control and in the presence of NCX blockers, C is the logarithm of concentration, and n is the Hill coefficient. n = 4 independent tests for each compound.
Abbreviation: NCX, Na + /Ca 2+ exchanger. 
| Inhibition of the Na + /Ca 2+ exchanger by its blockers in glioblastoma cells
We characterized the membrane currents associated with NCX activity in glioblastoma cells using whole-cell patch-clamp recording. As illustrated in Figure 1a , cell membrane potential was held at −50 mV, and the NCX currents were elicited by a voltage ramp from +60 to −120 mV. The NCX current in its reverse mode (Ca 2+ entry) was measured at +50, and the forward-mode current (Ca 2+ exit) was measured at −110 mV. The Ni 2+ (10 mM) was employed to inhibit and identify the NCX currents in its either reverse or forward mode as previously reported (Maack, Ganesan, Sidor, & O'Rourke, 2005) . The reversal potential of NCX current is around −60 mV determined by intersection of current-voltage relation (I/V) in the absence and presence of (c) In the Ca 2+ -free solution, Ca 2+ imaging of U87 cells before and after perfusion with bepridil or KB-R7943. (d) Ca 2+ imaging before and after perfusion with bepridil or KB-R7943, followed by application of 5-μM thapsigargin. (e) U87 cells were pretreated with a Ca 2+ chelator BAPTA-AM (20 μM) for 2 hr and then imaged and perfused with bepridil or KB-R7943. The traces are representative of three separate experiments, and n = 12-18 cells were imaged per experiment Ni 2+ . Bepridil has been reported to block forward-mode NCX and also partially inhibits its reverse mode . We found bepridil blocked both direction of NCX currents in U87 cells, with halfmaximal inhibition (IC 50 ) values of 19.1 ± 1.2 and 15.6 ± 1.1 μM ( Figure 1b and Table 1 ). KB-R7943 preferentially inhibits the reverse NCX, and it also blocks the forward NCX .
We found KB-R7943 inhibited the reverse NCX currents with an IC 50 value of 14.3 ± 1.2 μM, while suppressed its forward currents with an IC 50 = 32.3 ± 1.3 μM (Figure 1c and Table 1 ). SEA0400, SN-6, and YM244769 have good selectivity for the reverse NCX (Figure 1d-f ). They selectively block the reverse mode currents of NCX with IC 50 values of 3.6 ± 1.2, 3.2 ± 1.2, and 4.5 ± 1.1 μM, without inhibition of the forward NCX currents.
| Blocking the forward NCX operation generates cytotoxicity in glioblastoma cells
We next examined impact of NCX blockers on viability of glioblastoma cells. U87 and U251 cell lines were treated with bepridil or KB-R7943 for 72 hr. We found that viability of U87 and U251 cells was reduced to 30-40%, 6-7%, and 3-4% of control level by 20-, 50-, and 100-μM bepridil (Figure 2a,b) . Similarly, U87 and U251 cells were regressed to 50-60%, 7-18%, and 2-3% of control level by 20-, 50-, and 100-μM KB-R7943. Figure 2d lists IC 50 values of bepridil and KB-R7943 that cause cytotoxicity. Since bepridil and KB-R7943 inhibit both forward and reverse NCX, we need to clarify whether this cytotoxicity resulted from blocking the reverse or forward NCX operation.
To do so, three inhibitors (SEA0400, SN-6, and YM244769) selective for the reverse NCX were incubated with U87 and U251 cells at 5, 10, 20, 50, and 100 μM for 72 hr. We found that they exert much less impact on glioblastoma cells (Figure 2a,b) . SEA0400 at 10, 20, and 50 μM modulated U87 and U251 cell viability to 93-106%, 88-103%, and 72-92% of control level. SN-6 at 10, 20, and 50 μM modulated U87 and U251 cells to of 87-97%, 86-99%, and 74-104% of control level. YM244769 at 10, 20, and 50 μM suppressed U87 and U251 cells to 87-100%, 84-96%, and 71-76% of control level. So, the growth of glioblastoma cells is not affected when the reverse NCX is blocked.
We also applied NCX blockers to a paediatric glioblastoma cell line SF188. These cells were suppressed by bepridil and KB-R7943 in a dose-dependent manner but slightly affected by the compounds that selectively block the reverse NCX (Figure 2c ). CB-DMB is a more specific blocker for the forward NCX than bepridil and KB-R7943. It is very exciting to find that CB-DMB is more potent than bepridil and KB-R7943 in suppressing glioblastoma cells ( Figure S1a) . The IC 50 values of CB-DMB that cause cytotoxicity in U87, U251, and SF188 are 3.1 ± 0.6, 2.7 ± 0.1, and 2.6 ± 0.1 μM. These data confirm that blocking the forward but not reverse mode of NCX can suppress the growth of glioblastoma cells. containing solution and did not affect the ER Ca 2+ transporters ( Figure S1b-d) . The Na + imaging experiment with Na + indicator Asante NaTRIUM Green™ 2 (ANG-2) shows that bepridil and CB-DMB did not change the level of intracellular Na + [Na + ] i , while KB-R7943 slightly decreased [Na + ] i (Figure S2a-c) . Finally, there are no detectable NCX isoforms in the nuclei of U87 cells ( Figure S2d) (Brustovetsky et al., 2011) .
| Bepridil, CB-DMB, and KB-R7943 cause cell cycle arrest and apoptosis
To do cell cycle analysis, U87 cell cultures were treated with 25-μM bepridil for 6, 12, 18, and 24 hr and stained with PI. We show that bepridil reduced the cell fraction in S phase and increased cells in G 0 /G 1 phase in a time-dependent manner (Figure 4a,b) . To determine the role of [Ca 2+ ] i in bepridil-induced G 0 /G 1 arrest, BAPTA-AM was used to prevent [Ca 2+ ] i accumulation in U87 cells. Figure 4c shows that BAPTA-AM (10 μM) alone for 18 hr did not incur significant cell fraction changes in G 0 /G 1 , S and G 2 /M phases. Bepridil (25 μM, 18 hr) markedly increased cell fraction in G 0 /G 1 phase. This G 0 /G 1 arresting effect was significantly attenuated by 10-μM BAPTA-AM (Figure 4c ). To detect any apoptotic cell death involved, U87 cells were treated with bepridil (25 μM) for 6, 12, 24, and 48 hr and then analysed with Annexin V-FITC/PI apoptosis assay. Figure 4 d,e shows that bepridil incurred a time-dependent increase of apoptotic (Annexin V + ) cells. BAPTA-AM (10 μM) alone for 18 hr did not increase apoptosis in U87 cells but significantly attenuated bepridil-induced apoptosis (Figure 4f ). Application of CB-DMB (3.5 μM) to U87 cells also induced G 0 /G 1 arrest and activated apoptosis in time-dependent manner ( Figure S3a,b,d-e ), and these cell death processes were significantly attenuated by BAPTA-AM (Figure 3c,f) .
These data indicate that bepridil and CB-DMB generate cytotoxicity through Ca 2+ -mediated cell cycle arrest and apoptosis in glioblastoma cells.
KB-R7943 also caused G 0 /G 1 arrest and apoptosis in U87 cells, but Ca 2+ chelator BAPTA-AM cannot suppress these cell death processes (Figure 5a-d) . We notice that KB-R7943 is not a pure NCX blocker (Cheng, Zhang, Du, Dempsey, & Hancox, 2012) ; it also inhibits ionotropic glutamate NMDA receptors and mitochondrial respiratory complex 1 (Brustovetsky et al., 2011) . KB-R7943-induced cytotoxicity does not simply result from NCX inhibition and [Ca 2+ ] i elevation. Inhibition of respiratory chain complex 1 impairs mitochondrial oxidative phosphorylation and results in energy deficiency, which might contribute to the cytotoxicity of KB-R7943. Pharmacological action of KB-R7943 in this and past studies may need revisiting and re-evaluation in future.
| Involvement of MAPK signalling in bepridil-induced cell death
The above data indicate that bepridil killed glioblastoma cells via blockade of the forward NCX and elevation of [Ca 2+ ] i . It is well known that [Ca 2+ ] i regulates the MAPK signalling pathway, which plays essential role in cell fate determination (White & Sacks, 2010) . We here measured the activities of ERK, p38-MAPK, and JNK in U87 cells at the time points FIGURE 6 Bepridil induced activation of p38-MAPK and JNK signalling. (a) U87 cells were treated with bepridil at 25 μM for 10, 30, 60, and 90 min. The phosphorylated and total ERK, p38-MAPK, and JNK were detected by Western blot. Tubulin was an internal control. (b) Cells were pretreated with BAPTA-AM (10 μM) for 18 hr and then incubated with bepridil (25 μM) for 30 min. Activity of the p38-MAPK and JNK signalling was enhanced by bepridil but was attenuated in the presence of BAPTA-AM 10, 30, 60, and 90 min after incubation with 25-μM bepridil. Western blot analysis shows that ERK activity was not affected, but p38-MAPK and JNK were activated by bepridil throughout the selected time points (Figure 6a ). To examine the role of [Ca 2+ ] i in bepridil-induced MAPK activation, cells were pretreated with Ca 2+ chelator BAPTA-AM (10 μM) for 18 hr and then exposure to bepridil (25 μM) for 30 min. Figure 6b shows (Figure 7a,b) . This arresting effect was prevented by PD169316 but not CC-930, indicating that the p38-MAPK signalling is involved in bepridilinduced cell cycle arrest. The Annexin V apoptosis assay demonstrates that CC-930 and PD169316 did not activate apoptosis (Figure 7c,d) .
Bepridil (25 μM) increased the percentage of apoptotic cells after 24-hr incubation. This effect was attenuated by CC-930 but not PD169316, indicating that the JNK signalling is involved in bepridil-induced apoptosis.
3.6 | Functional expression of NCX isoforms and impact of bepridil on human astrocytes Glioblastoma arises from glial cells in the brain (Ostrom, Gittleman, Stetson, Virk, & Barnholtz-Sloan, 2018) . Bepridil was previously applied by Johnson & Johnson Pharmaceutical Research for the treatment of angina and hypertension. We here assessed viability of human astrocytes after exposed to bepridil (25 μM) for 48 hr and compared it with glioblastoma cells. Bepridil did not generate apparent cytotoxicity in human astrocytes, meanwhile markedly suppressed growth of U87, U251, and SF188 cells (Figure 8a ). To explore why human astrocyte is not sensitive to NCX blocker bepridil, we measured expression of three NCX isoforms in astrocytes and glioblastoma cells. Western blot analysis shows that NCX1 expression is significantly higher in human astrocytes than glioblastoma cells (Figure 8b ). But the level of NCX2 and NCX3 is . n = 5 independent tests in each group not high; especially, NCX2 is even lower than that in glioblastoma cells. This observation is identical to the literature, documenting that in astrocytes, NCX1 is the most highly expressed among the three NCX isoforms (Boscia et al., 2016; Pappalardo, Samad, Black, & Waxman, 2014) . We then decided to compare the activity of NCX among them by using whole-cell patch-clamp recording. The amplitude of the NCX currents in human astrocytes is much larger than glioblastoma cells (Figure 8c ). After performing a calculation, we show current density of the NCX in human astrocytes is several-fold higher than that in glioblastoma cells (Table S1 ). This high NCX activity and astrocyte's resistance to bepridil's toxicity most likely result from high expression of NCX1 isoform. On the other, KB-R7943 is deleterious to astrocytes probably due to its multiple actions besides blocking NCX (Figure 8d ).
FIGURE 9
Bepridil crosses the BBB and inhibits growth of brain-grafted glioblastoma. (a) Dotted box indicates the precursor to product ions (Q1 → Q3) selected for bepridil during quantitative optimization: 367.1 → 84.3 and 367.1 → 184.3 in positive ion mode. (b) Typical chromatogram of brain homogenate sample collected at 2 hr following systemic administration of bepridil (50 mg·kg −1 , p.o.). (c, d) Bioluminescent images of U87-luciferase glioblastoma cells implanted into the right cerebral striatum of nude mice. Images were taken by an IVIS Spectrum CT Imaging System before and after the period of treatment with bepridil or vehicle as described in methods. (e) Tumour size determined by bioluminescence and caliper measurement in each group before and after treatment. *P < .05, comparison between the two groups; n = 5 mice per group, analysed by Student's parametric unpaired t test 3.7 | Bepridil inhibits growth of brain-grafted tumour cells in vivo Bepridil has been shown to able to penetrate the blood-brain barrier (BBB) and reach the brain after oral administration or intraperitoneal injection at 50 mg·kg −1 body weight in two separate animal studies (Lipsanen et al., 2013; Mitterreiter et al., 2010) . Our MS experiment shows that bepridil can cross the BBB and get into brain tissue (Figure 9a,b) after oral administration. We then tested the effect of bepridil on the growth of established glioblastoma U87-Luc xenografts. U87-Luc cells were stereotactically injected into the right striatum of male nude mice. Sixteen days after intracranial implantation, bepridil (50 mg·kg −1 , p.o.) was administered once a day for 14 days.
Control group received the same amount of vehicle treatment.
Bioluminescent imaging of U87-Luc cells in live mice brain was performed before treatment began and after treatment finished. Tumour size was determined through quantitative bioluminescence of live cells expressing luciferase under the IVIS Spectrum CT Imaging System.
Vehicle treatment cannot hamper increasing tumour size, while bepridil successfully restrained tumour growth, yielding a significant volume difference between two groups (Figure 9c-e ). So, bepridil is also effective in suppressing growth of glioblastoma in vivo.
| DISCUSSION AND CONCLUSION
The Ca 2+ signalling in glioblastoma cells attracts increasing attention, and blockade of Ca 2+ permeable channels was advised as a strategy to cure glioblastoma (Alptekin et al., 2015; Ding et al., 2010; Leclerc et al., 2016; Zhang et al., 2017) . The present study proposes an alternative strategy other than blocking Ca 2+ entry; this new approach is to block the forward NCX (Ca 2+ exit mode) and cause Ca 2+ -mediated injury in glioblastoma cells. however, there is increasing evidence that KB-R7943 also inhibits many other ionic channels (Barrientos, Bose, Feng, Padilla, & Pessah, 2009; Brustovetsky et al., 2011; Pezier, Bobkov, & Ache, 2009 ). In our study, KB-R7943 is also toxic to normal astrocytes at the concentration range for it suppresses glioblastoma cells. We did not conduct further study to reveal intracellular signalling that mediates toxicity of KB-R7943.
Our test of bepridil generates more encouraging results. Bepridil can penetrate the BBB and reach the brain. Animal experiment demonstrated that bepridil reduces in vivo growth of brain-grafted glioblastoma. In addition, bepridil does not produce apparent cytotoxicity to human astrocytes when it markedly inhibits glioblastoma cells in vitro. This resistance to bepridil's cytotoxicity may result from high NCX1 expression and high NCX activity in astrocytes. The NCX1 expression is much lower in glioblastoma cells than in astrocytes. From the perspective of pharmacodynamics, the potency of a drug is proportional to the percentage of targets being occupied (Pugsley, Authier, & Curtis, 2008) . When most NCX1s on glioblastoma cells are occupied by bepridil at an appropriate concentration, only a small fraction of NCX1s are blocked in astrocytes. Therefore, viability of astrocytes is not affected by bepridil when it already hurts glioblastoma cells.
The present study cannot completely exclude the possibility that other mechanisms also contribute to the sensitivity difference between astrocytes and glioblastoma cells. For example, cytosolic Na + inactivates operation of the NCX1 and NCX3 (not NCX2), while increase of cytosolic Ca 2+ activates all NCXs and also alleviates the Na + -induced inactivation (Tal, Kozlovsky, Brisker, Giladi, & Khananshvili, 2016; Verkhratsky, Trebak, Perocchi, Khananshvili, & Sekler, 2018) . In glioblastoma cells, the elevated [Ca 2+ ] i cannot activate NCXs because most NCXs were occupied and blocked by bepridil. In human astrocytes, NCX1 is the most highly expressed isoform, and only a small portion of NCX1s were blocked by bepridil. The remaining
NCX1s can be readily activated by [Ca 2+ ] i and operate in the forward mode, which potentially underlies astrocyte's resistance to bepridil.
Second, the reverse NCX operation accounts for [Ca 2+ ] i overload and ensuing injury in astrocytes when these glial cells are in resting, stimulating, or ischaemic conditions, especially when Na + -driven uptake of neurotransmitters occurs (Reyes, Verkhratsky, & Parpura, 2012; Verkhratsky et al., 2018) . It is possible that the reverse NCXs were blocked by bepridil in human astrocytes, and thereafter, the cytotoxicity was regressed, whereas this situation is different in glioblastoma and the cytotoxicity was augmented because the forward NCXs were inhibited.
The role of NCX has been well described in glial cells by these articles (Boscia et al., 2016; Parpura, Sekler, & Fern, 2016; Rose & Verkhratsky, 2016) . But there are very few studies that report NCXs in the tissue of glioblastoma; particularly, it lacks data that compare NCXs between glioblastoma and glial cells. We here got a new observation that the NCX activity is higher in normal astrocytes than that in glioblastoma cells. The direction of NCX operation is controlled by change of membrane potential and gradients of Na + and Ca 2+ , which constantly coordinate with neuronal activity. Conversely, the NCX operation tightly regulates Na + and Ca 2+ signalling, which manipulates neuronal excitability and neurotransmission. Down-regulated NCX activity in glioblastoma could disrupt the crosstalk between glial and neuronal cells, leading to a detrimental ionic environment in the brain. So far, our materials verify our hypothesis and suggest that the plasma membrane NCX represents a new potential therapeutic target for glioblastoma.
Glioblastoma is the most common type of glioma that arises from glial cells in the brain or spinal cord. The annual incidence rate of glioblastoma in adults is between 0.6 and 3.7 per 100,000 persons (Ostrom et al., 2018) . Patients with glioblastoma usually have a mean survival rate of 3-4 months if without treatment (Krex et al., 2007; Rao, 2003) . Under combined treatment of radiotherapy and chemotherapy, the median survival time with grade IV glioblastoma can be prolonged to 15 months (Wen & Reardon, 2016) . Currently, there is no cure for human glioblastoma. The present pharmacological study demonstrates that blocking the forward NCX causes [Ca 2+ ] i accumulation and Ca 2+ -mediated demise of glioblastoma cells. Bepridil is effective in beating glioblastoma via blocking the forward NCX, thus may be used as a leading compound for developing new anti-tumour drugs.
Bepridil was previously approved by the Food and Drug Administration to treat angina but withdrawn later because it can induce new arrhythmias. We recommend that a structural modification is required to reduce the cardiac side effect of bepridil before it is re-purposed to treat human glioblastoma.
